$SESN this is from a week ago before the market drop started but I'm still very bullish. Happy with my adds below $2.70 today.
Shares of Sesen Bio Inc. continued their gains on the Nasdaq on Wednesday, a day after the company said the U.S. Food and Drug Administration accepted and granted priority review to its biologics license application for Vicineum for the treatment of a type of bladder cancer.
At 3:30 p.m. EST, the company's shares were trading 5.8% higher at $3.19. Volume at the time topped 16.1 million shares., above the stock's 65-day average volume of some 5.1 million.
On Tuesday, the stock closed 7.7% higher at $3.02, with volume of over 36.6 million shares.
Also Wednesday, HC Wainwright & Co. raised its price target on the company's stock to $8 per share from $2.25, and Canaccord Genuity raised its price target to $7 per share from $5, as reported by Benzinga.
.JPG)
